載入...
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer
PURPOSE: Cixutumumab, formerly IMC-A12, is a recombinant human monoclonal immunoglobulin G(1) antibody that targets insulin-like growth factor I receptor (IGF-IR). Cixutumumab was synergistic with castration in a hormone-sensitive prostate cancer xenograft model. PATIENTS AND METHODS: Patients with...
Na minha lista:
| 發表在: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Clinical Oncology
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4417730/ https://ncbi.nlm.nih.gov/pubmed/25847934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.4127 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|